Literature DB >> 24446761

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.

Per Damkier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24446761      PMCID： PMC4137836          DOI： 10.1111/bcp.12329

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

Review 1.  CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

Authors:  J M Rae
Journal:  Clin Pharmacol Ther       Date:  2013-08       Impact factor: 6.875

2.  CYP2D6 genotyping and the use of tamoxifen in breast cancer.

Authors:  Donald Berry
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

3.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

Authors:  Matthew P Goetz; James M Rae; Vera J Suman; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; David A Flockhart; Zeruesenay Desta; Edith A Perez; James N Ingle
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

4.  Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  James M Rae; Meredith M Regan; Jacklyn N Thibert; Christina Gersch; Dafydd Thomas; Brian Leyland-Jones; Giuseppe Viale; Lajos Pusztai; Daniel F Hayes; Todd Skaar; Catherine Van Poznak
Journal:  J Natl Cancer Inst       Date:  2013-08-19       Impact factor: 13.506

5.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Authors:  Timothy L Lash; Deirdre Cronin-Fenton; Thomas P Ahern; Carol L Rosenberg; Kathryn L Lunetta; Rebecca A Silliman; Jens Peter Garne; Henrik Toft Sørensen; Ylva Hellberg; Mariann Christensen; Lars Pedersen; Stephen Hamilton-Dutoit
Journal:  J Natl Cancer Inst       Date:  2011-02-15       Impact factor: 13.506

6.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.

Authors:  Catherine M Kelly; David N Juurlink; Tara Gomes; Minh Duong-Hua; Kathleen I Pritchard; Peter C Austin; Lawrence F Paszat
Journal:  BMJ       Date:  2010-02-08

7.  Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Carol L Rosenberg; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Clin Epidemiol       Date:  2010-10-22       Impact factor: 4.790

8.  Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.

Authors:  Hiltrud Brauch; Matthias Schwab
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

9.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Authors:  Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

10.  CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Authors:  M A Province; M P Goetz; H Brauch; D A Flockhart; J M Hebert; R Whaley; V J Suman; W Schroth; S Winter; H Zembutsu; T Mushiroda; W G Newman; M-T M Lee; C B Ambrosone; M W Beckmann; J-Y Choi; A-S Dieudonné; P A Fasching; R Ferraldeschi; L Gong; E Haschke-Becher; A Howell; L B Jordan; U Hamann; K Kiyotani; P Krippl; D Lambrechts; A Latif; U Langsenlehner; W Lorizio; P Neven; A T Nguyen; B-W Park; C A Purdie; P Quinlan; W Renner; M Schmidt; M Schwab; J-G Shin; J C Stingl; P Wegman; S Wingren; A H B Wu; E Ziv; G Zirpoli; A M Thompson; V C Jordan; Y Nakamura; R B Altman; M M Ames; R M Weinshilboum; M Eichelbaum; J N Ingle; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875
  10 in total
  2 in total

1.  CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.

Authors:  Hiltrud Brauch; Matthias Schwab
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 2.  Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.

Authors:  Feifei Cheng; Li Su; Cheng Qian
Journal:  Oncotarget       Date:  2016-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.